Related references
Note: Only part of the references are listed.Database of evidence for precision oncology portal
Sam Q. Sun et al.
BIOINFORMATICS (2018)
NRAS-mutant melanoma: current challenges and future prospect
Eva Munoz-Couselo et al.
ONCOTARGETS AND THERAPY (2017)
BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives
E. Sanz-Garcia et al.
ANNALS OF ONCOLOGY (2017)
Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials
Christophe Le Tourneau et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach
Junfei Zhao et al.
MOLECULAR & CELLULAR PROTEOMICS (2016)
Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials
Christophe Le Tourneau et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
Hui Zhang et al.
CELL (2016)
A Landscape of Pharmacogenomic Interactions in Cancer
Francesco Iorio et al.
CELL (2016)
A Description of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) Common Data Analysis Pipeline
Paul A. Rudnick et al.
JOURNAL OF PROTEOME RESEARCH (2016)
Proteogenomics connects somatic mutations to signalling in breast cancer
Philipp Mertins et al.
NATURE (2016)
Protein-structure-guided discovery of functional mutations across 19 cancer types
Beifang Niu et al.
NATURE GENETICS (2016)
In Silico Prescription of Anticancer Drugs to Cohorts of 28 Tumor Types Reveals Targeting Opportunities
Carlota Rubio-Perez et al.
CANCER CELL (2015)
The landscape of precision cancer medicine clinical trials in the United States
Nitin Roper et al.
CANCER TREATMENT REVIEWS (2015)
Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors
Ken Chen et al.
CLINICAL CHEMISTRY (2015)
The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform
Amber Johnson et al.
DRUG DISCOVERY TODAY (2015)
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31
Karen A. Gelmon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer
Tetsutaro Hayashi et al.
JOURNAL OF UROLOGY (2015)
Toward understanding and exploiting tumor heterogeneity
Ash A. Alizadeh et al.
NATURE MEDICINE (2015)
Comprehensive assessment of cancer missense mutation clustering in protein structures
Atanas Kamburov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
Laura R. Saunders et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Database of Genomic Biomarkers for Cancer Drugs and Clinical Targetability in Solid Tumors
Rodrigo Dienstmann et al.
CANCER DISCOVERY (2015)
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response
Himisha Beltran et al.
JAMA ONCOLOGY (2015)
Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK
Anthony W. Tolcher et al.
CLINICAL CANCER RESEARCH (2015)
The landscape and therapeutic relevance of cancer-associated transcript fusions
K. Yoshihara et al.
ONCOGENE (2015)
Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies
X-F Ye et al.
BRITISH JOURNAL OF CANCER (2014)
The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
Ian R. Watson et al.
CANCER RESEARCH (2014)
A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
Ho Yeong Lim et al.
CLINICAL CANCER RESEARCH (2014)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
Fabrice Andre et al.
LANCET ONCOLOGY (2014)
Proteogenomic characterization of human colon and rectal cancer
Bing Zhang et al.
NATURE (2014)
Discovery and saturation analysis of cancer genes across 21 tumour types
Michael S. Lawrence et al.
NATURE (2014)
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine
Eliezer M. Van Allen et al.
NATURE MEDICINE (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ClinVar: public archive of relationships among sequence variation and human phenotype
Melissa J. Landrum et al.
NUCLEIC ACIDS RESEARCH (2014)
Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
Filip Janku et al.
CELL REPORTS (2014)
PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
Filip Janku et al.
CANCER RESEARCH (2013)
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
Ayca Gucalp et al.
CLINICAL CANCER RESEARCH (2013)
Dramatic Response Induced by Vemurafenib in a BRAF V600E-Mutated Lung Adenocarcinoma
Solange Peters et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth et al.
NATURE (2013)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
TCPA: a resource for cancer functional proteomics data
Jun Li et al.
NATURE METHODS (2013)
DGIdb: mining the druggable genome
Malachi Griffith et al.
NATURE METHODS (2013)
Considerations for the successful co-development of targeted cancer therapies and companion diagnostics
Jane Fridlyand et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
Wanjuan Yang et al.
NUCLEIC ACIDS RESEARCH (2013)
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Andrea Sottoriva et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation
Cristian Tomasetti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Connecting Genomic Alterations to Cancer Biology with Proteomics: The NCI Clinical Proteomic Tumor Analysis Consortium
Matthew J. Ellis et al.
CANCER DISCOVERY (2013)
CancerDR: Cancer Drug Resistance Database
Rahul Kumar et al.
SCIENTIFIC REPORTS (2013)
Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
Ramaswamy Govindan et al.
CELL (2012)
The Origin and Evolution of Mutations in Acute Myeloid Leukemia
John S. Welch et al.
CELL (2012)
My Cancer Genome: a unified genomics and clinical trial portal
Charles Swanton
LANCET ONCOLOGY (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett et al.
NATURE (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
An integrated map of genetic variation from 1,092 human genomes
David M. Altshuler et al.
NATURE (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Xiaoyun Liao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Nikhil Wagle et al.
CANCER DISCOVERY (2012)
Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor-Positive Breast Cancer
Chungyeul Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
Sameek Roychowdhury et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
Xuchao Zhang et al.
MOLECULAR CANCER (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
A method and server for predicting damaging missense mutations
Ivan A. Adzhubei et al.
NATURE METHODS (2010)
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
Nilofer S. Azad et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Estrogen- and progesterone-receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory
Sunil S. Badve et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
HER2 status and benefit from adjuvant trastuzumab in breast cancer
Soonmyung Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer
Ronald M. Bukowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis
R. M. Bukowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer
Frederik Holst et al.
NATURE GENETICS (2007)
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain
Jeffrey C. Lee et al.
PLOS MEDICINE (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer
EK Rowinsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma
NA Dawson et al.
CLINICAL CANCER RESEARCH (2004)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial
MG Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
SIFT: predicting amino acid changes that affect protein function
PC Ng et al.
NUCLEIC ACIDS RESEARCH (2003)
Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998
CI Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The Ensembl genome database project
T Hubbard et al.
NUCLEIC ACIDS RESEARCH (2002)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
